Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
11/14/2016 Sanjiv S. Modi, M.B.B.S. Hematology & Medical Oncology PERSONAL Office Address: Contact: 2614 W. Jefferson Street, Joliet, IL 60435 Tel: Office (815) 725-1355 Cell (815) 405-6860 e-mail: [email protected] POSITIONS HELD July 1, 1994 to June 30, 1995 Intern, Department of Medicine University of Illinois at Chicago Chicago, IL 60612 July 1, 1995 to June 30, 1997 Senior Resident, Department of Medicine University of Illinois at Chicago Chicago, IL 60612 July 1, 1997 to June 30, 2000 Fellow, Section of Hematology & Oncology University of Illinois at Chicago Chicago, IL 60612 July 1, 1994 to June 30, 2000 Instructor in Medicine University of Illinois at Chicago Chicago, IL 60612 January 2008 to December 2008 Chairman, Cancer Committee Provena St. Joseph Medical Center, Joliet, IL January 2011 to December 2012 Page 1|8 11/14/2016 Chairman Cancer Committee Morris Hospital, Morris, IL January 1, 2007 to March 30, 2012 Medical Director of Clinical Research Joliet Oncology-Hematology Associates, LTD., Joliet, IL January 1, 2012 to December 2013 Chair Cancer Committee Morris Hospital, Morris, IL March 1, 2012 to July 2014 Medical Director of Continuing Medical Education Chairman Continuing Medical Education Committee Presence St. Joseph Medical Center, Joliet, IL PRESENT POSITION July 1, 2015 to Present Medical Director, Presence Kankakee Cancer Center, Kanakakee, IL January 1, 2014 to Present Member Cancer Committee Morris Hospital, Morris, IL November 1, 2012 to Present BANSAN LLC -Independent reviewer - Utilization Review, Disability review, worker's compensation review, Independent Medical Examiner, Peer Review, Expert Witness, Medical Legal Consultant August 1, 2000 to Present Medical Oncologist & Hematologist, Joliet Oncology-Hematology Associates, LTD., Joliet, IL EDUCATION & TRAINING 1997 - 2000 FELLOWSHIP University of Illinois at Chicago Chicago, IL 60612 Page 2|8 11/14/2016 1995 - 1997 RESIDENCY University of Illinois at Chicago Chicago, IL 60612 1994 – 1995 INTERNSHIP University of Illinois at Chicago Chicago, IL 60612 1991-1994 Migrated to USA and took Various Licensing examination required by ECFMG in order to qualify for Residency training in USA. 1990 – 1991 INTERNSHIP M.S. University Vadodara, India 1984 - 1990 M.B.B.S Maharaja Sayajirao University Vadodara, India CERTIFICATES & DIPLOMAS ABIM Board certified in Internal Medicine, 1997 & Recertified 2009 ABIM Board certified in Medical Oncology, 2001 & Recertified 2011 ABIM Board certified in Hematology, 2001& Recertified 2010 FMEGEMS I 1992 FLEX 1993 ECFMG 1993 USMLE II & III 1993 FLORIDA EXPERT WITNESS CERTIFICATE Valid Till 6/7/2017 HOSPITAL AFFILIATIONS Presence St. Joseph Medical Center. Joliet, IL Silver Cross Hospital. Joliet, IL Morris Hospital. Morris, IL LICENSURE State of Illinois, Licensure Number 036-093810 MEMBERSHIP IN PROFESSIONAL SOCIETIES American Society of Clinical Oncology American Society of Hematology Investigator Cancer Trial Support Unit Investigator Eastern Cooperative Oncology Group Page 3|8 11/14/2016 Forensic Expert Witness Association HONORS National Merit Scholarship Government of India PUBLICATIONS The final hours – Initiating early palliative care for advanced cancer patients The Patient 3rd issue 2015 pages 72-73 An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 2014 Apr 11;120(7):976-82. Epub 2013 Dec 11. Walter M Stadler, David J Vaughn, Guru Sonpavde, Nicholas J Vogelzang, Scott T Tagawa, Daniel P Petrylak, Peter Rosen, Chia-Chi Lin, John Mahoney, Sanjiv Modi, Peter Lee, Marc S Ernstoff, Wu-Chou Su, Alexander Spira, Korinna Pilz, Richard Vinisko, Charles Schloss, Holger Fritsch, Charles Zhao, Michael A Carducci Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2012 Jun 7;30(3):1211-5. Epub 2011 May 7. Manish R Sharma, Kristen Wroblewski, Blase N Polite, James A Knost, James A Wallace, Sanjiv Modi, Bethany G Sleckman, David Taber, Everett E Vokes, Walter M Stadler, Hedy L Kindler Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium Sonali M. Smith, Koen van Besien, Theodore Karrison, Janet Dancey, Peter McLaughlin, Anas Younes, Scott Smith, Patrick Stiff, Eric Lester, Sanjiv Modi, L. Austin Doyle, Everett E. Vokes, and Barbara Pro JCO Nov 1, 2010:4740-4746; published online on September 13, 2010; DOI:10.1200 Journal of Clinical Oncology.2010.29.2813. Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes. Roger M. Lyons, Thomas M. Cosgriff, Sanjiv S. Modi, Robert H. Gersh, John D. Hainsworth, Allen L. Cohn, Heidi J. McIntyre, Indra J. Fernando, Jay T. Backstrom, C.L. Beach Journal of Clinical Oncology, Vol 27, No 11 (April 10), 2009: pp. 1850-1856 Molecular Inhibition of mTOR with Temsirolimus (TORISEL , CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium. Session Type: Poster Session, Board #661-II Sonali M. Smith, Barbara Pro, Scott Smith, Patrick Stiff, Eric Lester, Sanjiv Modi, Janet Dancey, Everett E. Vokes, Koen van Besien Page 4|8 11/14/2016 Azacitidine (Vidaza®) Treatment Response Assessed Using Three Alternative Dosing Schedules in Patients with Myelodysplastic Syndromes (MDS). Roger Lyons, MD, Thomas Cosgriff, MD, Sanjiv Modi, MD, Linda Lintz, BA*, C.L. Beach, PharmD4,* and Jay T. Backstrom, MD, MPH4 Blood (ASH Annual Meeting Abstracts) 2005 106: Abstract 2517 All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells. Yazan Alsayeda, Sanjiv Modia, Shahab Uddina, Nadim Mahmuda, Brian J. Drukerb, Eleanor N. Fishc, Ronald Hoffmana and Leonidas C. Platanias Experimental Hematology Volume 28, Issue 7, July 2000, Pages 826-832 Interferon-Dependent Activation of the Serine Kinase PI 3′-Kinase Requires Engagement of the IRS Pathway but Not the Stat Pathway. Shahab Uddin, Beata Majchrzak, Pu-Chen Wang, Sanjiv Modi, Mohammad K. Khan, Eleanor N. Fish and Leonidas C. Platanias Biochemical and Biophysical Research Communications Volume 270, Issue 1, 2 April 2000, Pages 158-162 Modulation of Interleukin-6/Interleukin-6 Receptor Cytokine Loop in the Treatment of Multiple Myeloma. Yi-Hsiang Chen; Rei-Tsang Shiao; Jo-Mel Labayog; Sanjiv Modi; Donald Lavelle Leukemia and Lymphoma, Volume 27, Issue 1 & 2 September 1997, pages 11 – 23 SCIENTIFIC PRESENTATIONS June 6, 2004 - Lung Cancer for Primary Care Physicians - Saint Joseph Medical Center Grand Rounds August 16, 2007 Azacitidine Alternate Dose Regimens – Joliet Oncology Hematology Associates October 18, 2010 – Polycythemia Vera - Joliet Oncology Hematology Associates November 12, 2010 – Heparin Induced Thrombocytopenia – Provena St. Joseph Medical Center Grand Rounds July 25, 2012- Multiple Myeloma - Joliet Oncology Hematology Associates August 7, 2013 – Myelodysplastic Syndrome - Joliet Oncology Hematology Associates September 20, 2014 – Newer Oral Anticoagulants – Presence Cancer Care Annual Symposium August 5, 2015 – Myelodysplastic Syndrome – Presence Saint Joseph Medical Center October 10, 2015 – Personalized Medicine – Presence Cancer Care Annual Symposium 2015 – 2016 Invited Speaker Janssen Pharmaceuticals - Xarelto to treat thrombosis and reduce thrombotic risk Page 5|8 11/14/2016 2016 - Invited Speaker Bristol Myers Squibb – Eliquis to treat thrombosis and reduce thrombotic risk RESEARCH EXPERIENCE A DUAL-COHORT, PROSPECTIVE, OBSERVATIONAL STUDY OF UNSTABLE STAGE IIIB/IV NSCLC PATIENTS WITH AND WITHOUT BONE METASTASIS AN OBSERVATION STUDY OF TREATMENT, OUTCOMES, AND PROGONSIS IN PATIENTS WITH FOLLICULAR NON-HODGKIN’S LYMPHOMA PHASE III RANDOMIZED STUDY OF XXX IN COMBINATION WITH XXX VERSES XXX AS SECOND LINE THERAPY IN PLATINUM REFRACTORY OR RESISTANT OVARIAN CANCER A RANDOMIZED OPEN-LABEL, CONTROLLED, CLINICAL TRIAL OF CHEMOTHERAPY AND XXX WITH AND WITHOUT XXX IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH METASTATIC COLORECTAL CANCER A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THREE ALTERNATIVE DOSING REGIMENS OF SUBCUTANEOUS XXX PLUS BEST SUPPORTIVE CARE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES A RANDOMIZED, OPEN-LABEL TRIAL COMPARING TWO METHODS OF XXX BASED THERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER AN OBSERVATIONAL COHORT STUDY OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER A RANDOMIZED, MULTICENTER STUDY OF COMBINATION XXX THERAPY FOLLOWED BY SUBSEQUENT SINGLE AGENT XXX MAINTENANCE THREAPY OR BEST SUPPORTIVE CARE IN ADVANCED NSCLC FEASIBILITY OF A REDUCED XXX PRE- MEDICATION DOSE IN ELDERLY PATIENTS TREATED WITH WEEKLY XXX A NATIONAL WEB-BASED RANDOMIZED PHASE III STUDY OF XXX OR PLACEBO FOLLOWING CONCURRENT XXX, XXX AND THORACIC RADIOTHERAPY IN PATIENTS WITH INOPERABLE STAGE III NSCLC A RANDOMIZED STUDY OF INTERMITTENT XXX IN COMBINATION WITH XXX AND XXX VERSUS INTERMITTENT XXX IN COMBINATION WITH XXX AND XXX AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER A PHASE III, MULTICENTER, PLACEBO- CONTROLLED DOUBLE-BLIND RANDOMIZEDCLINICAL TRIAL TO EVALUATE THE EFFICACY OF XXX IN COMBINATION WITH XXX COMPARED WITH XXX ALONE FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER AFTER FAILURE OF STANDARD FIRST-LINE CHEMOTHERAPY A STUDY TO ASSESS THE IMPACT OF ONCE PER CYCLE CORRECTION AND MAINTENANCE DOSING OF XXX IN SUBJECTS WITH NON-MYELOID MALIGNANCIES WITH ANEMIA DUE TO CHEMOTHERAPY Page 6|8 11/14/2016 A PHASE III RANDOMIZED TRIAL OF XXX BASED INDUCTION CHEMOTHERAPY IN PATIENTS WITH N2/N3 LOCALLY ADVANCED HEAD AN NECK CANCER A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF XXX IN COMBINATION WITH CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED METASTATIC BREAST CANCER A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF XXX IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC BREAST CANCER A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, 18 WEEK PILOT STUDY TO INVESTIGATE THE NEUROPROTECTIVE EFFECT OF XXX ON THE DEVELOPMENT OF PERIPHERAL NEUROPATHY IN PATIENTS RECEIVING CHEMOTHERAPY FOR ADVANCED OVARIAN CANCER A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH METASTATIC COLORECTAL CANCER PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH NSCLC A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH RECURRENT OVARIAN CANCER A PHASE II STUDY OF XXX ADMINISTERED INTRAVENOUSLY TO SUBJECTS WITH METASTATIC RENAL CELL CARCINOMA A PHASE II STUDY OF INTRAVENOUS XXX IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM A DOUBLE – BLIND, PLACEBO CONTROLLED EVALUATION OF THE EFICACY, SAFETY AND TOLERABILITY OF XXX IN THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER SUBJECTS AN OPEN LABEL, LONG-TERM TREATMENT EVALUATION OF THE SAFETY OF XXX USE FOR BREAKTHROUGH PAIN IN CANCER SUBJECTS ON CHRONIC OPIOID THERAPY A MULTIPLE-DOSE, NON RANDOMIZED, OPEN-LABLE, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF XXX IN THE TREATMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS XXX VS XXX WOMEN WITH CHEMOTHERAPY-NAÏVE ADVANCED NSCLC WHO ARE PERFORMANCE STATUS 2 A RANDOMIZED DOUBLE-BLIND, MULTICENTER PHASE STUDY OF THE EFFICACY OF XXX IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC AFTER FAILURE OF FIRST–LINE ANTI CANCER THERAPY A PHASE III RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF XXX AND XXX VS XXX AND PLACEBO N PATIENTS WITH ADVANCED STAGE IIIB/IV NSCLC AFTER FAILURE OF XXX BASED CHEMOTHERAPY A PHASE III RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF XXX AND XXX VS XXX IN PATIENTS WITH ADVANCED STAGE IIIB/IV NSCLC AFTER FAILURE OF XXX BASED CHEMOTHERAPY Page 7|8 11/14/2016 PHASE III RANDOMIZED, STUDY OF XXX VS XXX AS THIRD-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC A TWO- STAGE TRIAL OF XXX IN COMBINATION WITH WEEKLY XXX FOR TREATMENT OF PATIENTS WITH METASTATIC MELANOMA VOLUNTEER WORK Director JOHA Foundation (non profit arm of Joliet Oncology Hematology Associates LTD.) Secretary for North South Foundation since 2009 President Bansan Foundation Served on Hindu Temple of Greater Chicago Finance Committee in 2007-2008 Page 8|8